James Bruce McAlpine

James Bruce McAlpine

Auto-generated profile, based on publicly available information

James Bruce McAlpine

University of Illinois Chicago

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2018 in Journal of Natural Products
Verified
Journal Article
Closed access
YLYang Liu
Yang Liu
JFJ. Brent Friesen
J. Brent Friesen
JMJames B. McAlpine
James B. McAlpine
DLDavid C. Lankin
David C. Lankin
SCShao-Nong Chen
Shao-Nong Chen
GPGuido F. Pauli
Guido F. Pauli

13 July 2018 in Natural Product Reports
Verified
Journal Article
Open access
PDF file
JMJames B. McAlpine
James B. McAlpine
SCShao-Nong Chen
Shao-Nong Chen
AKAndrei G. Kutateladze
Andrei G. Kutateladze
JMJohn B MacMillan
John B MacMillan
Giovanni AppendinoGiovanni Appendino
Giovanni Appendino
GPGuido F. Pauli
Guido F. Pauli
With contributions from the global natural product (NP) research community, and continuing the Raw Data Initiative, this review collects a comprehensive demonstration of the immense scientific value of disseminating raw nuclear magnetic resonance (NMR) data, independently of, and in parallel with, classical publishing outlets.

7 February 2020 in Journal of Natural Products
Verified
Journal Article
Open access
BZBin Zhou
Bin Zhou
GSGauri Shetye
Gauri Shetye
YYYang Yu
Yang Yu
BSBernard D. Santarsiero
Bernard D. Santarsiero
LKLarry L. Klein
Larry L. Klein
GPGuido F. Pauli
Guido F. Pauli
This study represents a systematic chemical and biological study of the rufomycin (RUF) class of cyclic heptapeptides, which our anti-TB drug discovery efforts have identified as potentially promising anti-TB agents that newly target the caseinolytic protein C1, ClpC1. Eight new RUF analogues, rufomycins NBZ1–NBZ8 (1–8), as well as five known peptides (9–13) were isolated and characterized from the Streptomyces atratus strain MJM3502. Advanced Marfey’s and X-ray crystallographic analysis led to the assignment of the absolute configuration of the RUFs. Several isolates exhibited potent activity against both pathogens M. tuberculosis H37Rv and M. abscessus, paired with favorable selectivity (selectivity index >60), which collectively underscores the promise of the rufomycins as potential anti-TB drug leads.

1 February 2019 in Dental Materials
Verified
Journal Article
Closed access
BABerdan Aydin
Berdan Aydin
ALAriene A. Leme-Kraus
Ariene A. Leme-Kraus
CVCristina M.P. Vidal
Cristina M.P. Vidal
TAThaiane R. Aguiar
Thaiane R. Aguiar
RPRasika S. Phansalkar
Rasika S. Phansalkar
ABAna K. Bedran-Russo
Ana K. Bedran-Russo

24 May 2018 in The Journal of Organic Chemistry
Verified
Journal Article
Open access
MCMary P Choules
Mary P Choules
LKLarry L. Klein
Larry L. Klein
DLDavid C. Lankin
David C. Lankin
JMJames B. McAlpine
James B. McAlpine
SCSang-Hyun Cho
Sang-Hyun Cho
GPGuido F. Pauli
Guido F. Pauli
Residual complexity (RC) involves the impact of subtle but critical structural and biological features on drug lead validation, including unexplained effects related to unidentified impurities. RC commonly plagues drug discovery efforts due to the inherent imperfections of chromatographic separation methods. The new diketopiperazine, rufomyazine (6), and the previously known antibiotic, rufomycin (7), represent a prototypical case of RC that (almost) resulted in the misassignment of biological activity. The case exemplifies that impurities well below the natural abundance of 13C (1.1%) can be highly relevant and calls for advanced analytical characterization of drug leads with extended molar dynamic ranges of >1:1,000 using qNMR and LC-MS. Isolated from an actinomycete strain, 6 was originally found to be active against Mycobacterium tuberculosis with a minimum inhibitory concentration (MIC) of 2 μg/mL and high selectivity. As a part of lead validation, the dipeptide was synthesized and surprisingly found to be inactive. The initially observed activity was eventually attributed to a very minor contamination (0.24% [m/m]) with a highly active cyclic peptide (MIC ∼ 0.02 μM), subsequently identified as an analogue of 7. This study illustrates the serious implications RC can exert on organic chemistry and drug discovery, and what efforts are vital to improve lead validation and efficiency, especially in NP-related drug discovery programs.

10 October 2021 in Journal of Natural Products
Verified
Journal Article
Closed access
BZBin Zhou
Bin Zhou
PAPrabhakar S. Achanta
Prabhakar S. Achanta
GSGauri Shetye
Gauri Shetye
SCShao-Nong Chen
Shao-Nong Chen
HLHyun Lee
Hyun Lee
JMJames B. McAlpine
James B. McAlpine